WHO Drug Information Vol. 24, No. 4, 2010

More documents

Recommendations

Info

Proposed INN: List 104 WHO Drug Information, Vol. 24, No. 4, 2010naronaprida6-[(3S,4R)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il]hexanoato de (3R)-1-azabiciclo[2.2.2]octan-3-iloantagonista de los receptores de la dopaminaC 27 H 41 ClN 4 O 5 860174-12-5ClH 2 NOHNHOCH 3ONHONonartuzumabum #onartuzumabonartuzumabimmunoglobulin G1-kappa monovalent Fab-Fc, anti-[Homo sapiensMET (met proto-oncogene, hepatocyte growth factor receptor,HGFR, scatter factor receptor, HGF/SF receptor, receptor tyrosineproteinkinase c-Met, papillary renal cell carcinoma 2, RCCP2)],humanized monoclonal antibody;gamma1 heavy chain (1-449) [humanized VH (Homo sapiensIGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homosapiens IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368),L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfide withkappa light chain (1'-220') [humanized V-KAPPA (Homo sapiensIGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiensIGKC*01 (114'-220')], (228-6'':231-9'')-bisdisulfide with truncatedgamma1 chain consisting of partial hinge-CH2-CH3 (1"-227") [Homosapiens IGHG1*01 hinge 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W (146")]antineoplasticimmunoglobuline G1-kappa monovalent Fab-Fc, anti-[Homo sapiensMET (proto-oncogène met, récepteur du facteur de croissancehépatocytaire, HGFR, récepteur du facteur de dispersion, récepteurde l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinomepapillaire à cellules rénales 2, RCCP2)], anticorps monoclonalhumanisé;chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiensIGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homosapiens IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368),L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfure avec lachaîne légère kappa (1'-220') [V-KAPPA humanisé (Homo sapiensIGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiensIGKC*01 (114'-220')], (228-6'':231-9'')-bisdisulfure avec la chaînegamma1 tronquée comprenant charnière partielle-CH2-CH3 (1"-227") [Homo sapiens IGHG1*01 charnière 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W(146")]antinéoplasique384
WHO Drug Information, Vol. 24, No. 4, 2010 Proposed INN: List 104onartuzumabinmunoglobulina G1-kappa monovalente Fab-Fc, anti-[Homosapiens MET (protooncogén met, receptor del factor de crecimientohepatocitario, HGFR, receptor del factor de dispersión, receptor del'HGF/SF, receptor de tirosina proteín-kinasa c-Met, carcinomapapilar de cèlulas renales 2, RCCP2)], anticuerpo monoclonalhumanizado;cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiensIGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homosapiens IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368),L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfuro con lacadena ligera kappa (1'-220') [V-KAPPA humanizada (Homo sapiensIGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -Homo sapiensIGKC*01 (114'-220')], (228-6'':231-9'')-bisdisulfuro con la cadenagamma1 truncada que comprende parte de la bisagra-CH2-CH3 (1"-227") [Homo sapiens IGHG1*01 bisagra 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W(146")]antineoplásico1133766-06-9Heavy chain / Chaîne lourde / Cadena pesada (H)EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYWLHWVRQA PGKGLEWVGM 50IDPSNSDTRF NPNFKDRFTI SADTSKNTAY LQMNSLRAED TAVYYCATYR 100SYVTPLDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449Light chain / Chaîne légère / Cadena ligera (L)DIQMTQSPSS LSASVGDRVT ITCKSSQSLL YTSSQKNYLA WYQQKPGKAP 50KLLIYWASTR ESGVPSRFSG SGSGTDFTLT ISSLQPEDFA TYYCQQYYAY 100PWTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200EVTHQGLSSP VTKSFNRGEC 220Hinge-CH2-CH3 / Charnière-CH2-CH3/ Bisagra-CH2-CH3 (H'')DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 50PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 100CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLWCLVK 150GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 200NVFSCSVMHE ALHNHYTQKS LSLSPGK 227Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 146-202 263-323 369-427Intra-H'' 41''-101'' 147''-205''Intra-L 23'-94' 140'-200'Inter-H-L 222-220'Inter-H-H'' 228-6'' 231-9''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación299, 77'' unglycosylated as expressed in Escherichia coliordopidinumordopidineordopidineordopidina1-ethyl-4-[2-fluoro-3-(methanesulfonyl)phenyl]piperidineantiparkinsonian1-éthyl-4-[2-fluoro-3-(méthylsulfonyl)phényl]pipéridineantiparkinsonien1-etil-4-[2-fluoro-3-(metanosulfonil)fenil]piperidinaantiparkinsoniano385
Page 1 and 2:
WHO Drug Information Vol. 24, No. 4
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44: WHO Drug Information Vol. 24, No. 4
Page 61 and 62: WHO Drug Information, Vol. 24, No.
Page 93: WHO Drug Information, Vol. 24, No.
show all

WHO Drug Information Vol. 24, No. 4, 2010

Create successful ePaper yourself

Delete template?

Save as template?